Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$25.72 - $29.94 $62,756 - $73,053
-2,440 Reduced 20.74%
9,324 $252,000
Q4 2023

Feb 14, 2024

SELL
$23.42 - $31.74 $10,234 - $13,870
-437 Reduced 3.58%
11,764 $364,000
Q3 2023

Nov 14, 2023

SELL
$19.86 - $26.93 $605,968 - $821,688
-30,512 Reduced 71.43%
12,201 $308,000
Q2 2023

Aug 14, 2023

BUY
$16.44 - $21.1 $40,919 - $52,517
2,489 Added 6.19%
42,713 $901,000
Q1 2023

May 15, 2023

BUY
$16.26 - $21.73 $281,184 - $375,776
17,293 Added 75.41%
40,224 $685,000
Q4 2022

Feb 14, 2023

SELL
$16.98 - $23.15 $361,283 - $492,562
-21,277 Reduced 48.13%
22,931 $458,000
Q3 2022

Nov 08, 2022

BUY
$20.88 - $28.21 $568,228 - $767,706
27,214 Added 160.14%
44,208 $952,000
Q2 2022

Aug 15, 2022

SELL
$17.07 - $25.71 $82,448 - $124,179
-4,830 Reduced 22.13%
16,994 $335,000
Q1 2022

May 16, 2022

SELL
$20.42 - $28.13 $441,480 - $608,170
-21,620 Reduced 49.77%
21,824 $513,000
Q4 2021

Feb 14, 2022

BUY
$25.89 - $33.45 $1.12 Million - $1.45 Million
43,444 New
43,444 $1.18 Million
Q4 2019

Feb 13, 2020

SELL
$16.12 - $24.98 $4.78 Million - $7.4 Million
-296,365 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$15.49 - $25.78 $2.95 Million - $4.91 Million
-190,610 Reduced 39.14%
296,365 $5.23 Million
Q2 2019

Aug 14, 2019

BUY
$23.0 - $32.19 $3.67 Million - $5.13 Million
159,391 Added 48.66%
486,975 $12.5 Million
Q1 2019

May 15, 2019

SELL
$13.91 - $31.15 $6.71 Million - $15 Million
-482,300 Reduced 59.55%
327,584 $9.52 Million
Q4 2018

Feb 14, 2019

BUY
$11.6 - $18.7 $9.39 Million - $15.1 Million
809,884 New
809,884 $10.6 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.48B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Atom Investors LP Portfolio

Follow Atom Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Atom Investors LP with notifications on news.